Strategic Transaction Advances Company’s GrowthSARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The ...

Core Insights - INVO Fertility, Inc. has received a U.S. patent for a modified version of its INVOcell device, extending intellectual property protection until 2040 [1][4] - The INVOcell device is the first FDA-cleared intravaginal culture system, allowing fertilization and early embryo development within a woman's body, providing a more natural alternative to traditional IVF [2][5] Group 1: Patent and Intellectual Property - The newly issued patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, marking a significant milestone for the company [1][4] - The patent covers a simplified design of the INVOcell device, which has been developed based on clinical feedback and real-world use [3] Group 2: Product and Market Position - INVOcell was initially granted FDA clearance in 2015 and received an update in 2023 to extend the recommended incubation period from three days to five days [3] - The INVOcell procedure is designed to provide a more connected and affordable experience for patients compared to traditional ART treatments, with the potential for comparable results at a lower cost [5]

Core Viewpoint - INVO Fertility, Inc. is positioned for growth with a strengthened fundamental position, focusing on operational progress, disciplined capital management, and a clear growth strategy [3][4][21]. Operational Progress - The company has three operational fertility clinics generating positive cash flow, marking a critical milestone in achieving profitability at the clinic level [5]. - INVO Fertility is nearing the acquisition of a fourth clinic in Indianapolis, which will diversify revenue and enhance earnings power [6]. Financial Performance - The combined pro forma annualized revenue run rate from all clinics is approximately $9 million, providing a strong baseline for growth [7]. - The company has simplified and strengthened its capital structure, with recent financing issued at a fixed price of $1.59, enhancing clarity and alignment for shareholders [16][17]. Growth Strategy - Organic growth is a key component of the strategy, focusing on increasing patient volumes and optimizing treatment pathways [8][9]. - Acquisitions are a cornerstone of growth, with a robust pipeline of potential targets under evaluation, emphasizing clinics with strong reputations and operational improvement opportunities [10][11][12]. Market Environment - Recent executive actions support federal access to IVF and fertility treatments, potentially increasing patient demand and utilization of fertility services [13]. - The company anticipates strong growth in 2026, driven by acquisitions and organic expansion, addressing the rising global infertility rates and limited access to affordable services [14][15]. Future Outlook - INVO Fertility is positioned for a higher-growth phase with a stabilized operational base and a strong balance sheet, aiming to build a scalable platform for sustained growth [19][21].

As filed with the U.S. Securities and Exchange Commission on February 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878-9505 (Addres ...

As filed with the U.S. Securities and Exchange Commission on February 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878- ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - Smart Logistics Global Limited (SLGB) is up 198% at $3.67 [3] - Brand Engagement Network, Inc. (BNAI) is up 67% at $10.29 [3] - Boxlight Corporation (BOXL) is up 56% at $1.96 [3] - Moolec Science SA (MLEC) is up 51% at $6.64 [3] - Anteris Technologies Global Corp. (AVR) is up 15% at $6.63 [3] - Hycroft Mining Holding Corporation (HYMC) is up 10% at $47.20 [3] - Nathan's Famous, Inc. (NATH) is up 8% at $100.94 [3] - Progress Software Corporation (PRGS) is up 6% at $41.05 [3] - LightPath Technologies, Inc. (LPTH) is up 5% at $14.81 [3] - ZenaTech, Inc. (ZENA) is up 5% at $4.33 [3] Group 2: Premarket Losers - Top Wealth Group Holding Limited (TWG) is down 29% at $3.81 [4] - Solo Brands, Inc. (SBDS) is down 21% at $5.25 [4] - GlucoTrack, Inc. (GCTK) is down 19% at $3.07 [4] - Galaxy Payroll Group Limited (GLXG) is down 19% at $2.26 [4] - INVO Fertility, Inc. (IVF) is down 13% at $2.04 [4] - Black Titan Corporation (BTTC) is down 11% at $2.11 [4] - Envirotech Vehicles, Inc. (EVTV) is down 10% at $3.30 [4] - Erasca, Inc. (ERAS) is down 6% at $9.21 [4] - ENDRA Life Sciences Inc. (NDRA) is down 6% at $4.31 [4] - Bonk, Inc. (BNKK) is down 6% at $3.74 [4]

Company Overview - INVO Fertility, Inc. is a healthcare fertility company focused on establishing, acquiring, and operating fertility clinics and related technologies [3] - The company operates two INVO Centers and one IVF clinic in the United States, and it sells the INVOcell medical device to third-party fertility clinics [3] - INVOcell is a proprietary medical device that allows fertilization and early embryo development to occur in vivo within the woman's body, offering a more intimate and affordable experience compared to traditional ART treatments [3] Upcoming Event - INVO Fertility will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026, at 3:00 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2]

Core Viewpoint - INVO Fertility, Inc. has announced a realignment of its executive leadership team to better support its growth strategy focused on the establishment and acquisition of fertility clinics and related businesses [1][3]. Leadership Changes - Terah Krigsvold has been appointed as the new Chief Financial Officer (CFO), replacing Andrea Goren, who will now serve as Chief Business Officer and CEO of INVO Centers LLC, a subsidiary focused on fertility clinics [2][3]. - The leadership changes are intended to enhance the company's ability to execute its growth plan and achieve profitability [3]. Company Strategy - INVO Fertility is dedicated to expanding access to assisted reproductive technology (ART) and focuses on building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [4]. - The company currently operates two INVO Centers and one IVF clinic in the United States and is involved in the sale and distribution of the INVOcell device to third-party clinics [4]. Product Offering - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more intimate and affordable experience compared to traditional ART treatments [4]. - The IVC procedure enabled by INVOcell is believed to deliver comparable results to traditional IVF at a significantly lower cost and is more effective than intrauterine insemination [4].

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...